Compare Medpace Holdings Inc (MEDP) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Atlassian Corporation PLC — how do they compare? Medpace Holdings Inc trades at $532.89 (market cap $15.08B), while Atlassian Corporation PLC trades at $90.16 (market cap $23.67B). The key difference: Atlassian Corporation PLC is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| MEDP | TEAM | |
|---|---|---|
Market Cap | $15.08B | $23.67B |
Sector | Technology | Technology |
52-Week High | $620.59 | $203.00 |
52-Week Low | $308.88 | $57.15 |
Enterprise Value | $14.55B | $23.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
TEAM trades at $96.63, up 3.58% with bullish technical signals and strong analyst support. Revenue growth accelerated to $5.22B in 2025, though net margins remain negative at -4.93%. Recent AI-driven product launches and service collection surpassing $1B ARR highlight innovation momentum. The stock faces resistance near $97 with support at $92.
Outlook remains positive given consensus price target of $114.54 (18.5% upside) and 29 buy ratings. Risks include persistent unprofitability, competitive pressure from Microsoft/ServiceNow, and projected negative cash flow in 2026. Valuation appears reasonable with P/S of 3.96 versus sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
